Dr Scott J Turner | Specialist Plastic Surgeon (FRACS) | Sydney
If you’ve found this page, you’re probably worried about cancer. The short version is that BIA-ALCL is rare, it’s mostly linked to a specific group of textured implants that were pulled from the Australian market in 2019, and most patients with current implants will never develop it. The longer version, which is what this guide covers, is what BIA-ALCL actually is, what symptoms to keep an eye out for, what your real risk looks like based on your implant type, and what happens if it ever needs to be investigated.
I’m Dr Scott J Turner, a Specialist Plastic Surgeon (FRACS) at our Bondi Junction and Manly clinics in Sydney.
What BIA-ALCL Is, in Plain English
BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. It’s a rare cancer of immune cells that can develop in the fluid or scar tissue around certain breast implants. The important word there is “around.” It isn’t breast cancer, it doesn’t grow from breast tissue, and it doesn’t behave like breast cancer. Most cases show up between three and fourteen years after the original implant surgery, with eight years being the most common. When it’s caught early and the implants are removed properly, most patients do well.
The clearest pattern across thousands of cases worldwide is that BIA-ALCL is overwhelmingly linked to textured implants, particularly the rougher macro-textured kind. There are no confirmed Australian cases in patients who have only ever had smooth implants. Researchers think the disease develops from a combination of long-term inflammation at the textured implant surface (sometimes involving bacterial biofilm) and the patient’s own immune or genetic makeup. The texture matters more than the silicone or saline filling.
Your Risk Depends on the Implant You Have
The single most useful question for understanding your risk is what type of implant you actually have. The figures below are best-available estimates rather than precise numbers, because BIA-ALCL is under-reported and the totals are based on estimated implant sales rather than exact patient counts. They’re broadly accurate as a guide, but they’ll keep refining as more data comes in.
The TGA’s broad category estimates, based on cases reported up to the end of 2021, give you a sense of the picture. Polyurethane-coated implants carry the highest estimated risk at roughly 1 in 1,800. These haven’t been on the Australian market for years, but some patients still have them. Macro-textured implants come in around 1 in 2,400. The most well-known of these is the Allergan Biocell range, which was suspended from the Australian market in October 2019 after the data showed disproportionately high cancer rates. Micro-textured implants sit at around 1 in 18,000. And smooth implants have no confirmed Australian cases linked to them at all.
More recent manufacturer-specific research goes further. Allergan Biocell macro-textured implants are now estimated at roughly 1 in 2,000 to 1 in 8,500 depending on the cohort studied. Mentor Siltex micro-textured implants, which Dr Turner uses in current practice when textured implants are clinically indicated, sit at the low end of textured-implant risk: around 1 in 36,000 to 1 in 50,000. A 2025 systematic review of manufacturers found that approximately 86% of all reported BIA-ALCL cases globally were linked to Allergan devices, with Mentor accounting for roughly 5% of cases.
What this means in practice: if you have Mentor Siltex implants, your risk is genuinely low but it isn’t zero. If you have older macro-textured implants still in place, your risk is higher than the average textured-implant patient. If you have smooth implants, your risk of BIA-ALCL specifically is very low. None of these scenarios mean you need surgery if you have no symptoms.
Why Australia Has a Higher Share of Cases
Roughly 10 to 15 percent of all reported BIA-ALCL cases worldwide come from Australia. This isn’t because Australian patients are at higher individual risk. It’s because of two specific factors. The first is that until around 2016, about 85% of breast implants used in Australia were textured. In the United States, by contrast, 70 to 90% of implants used were smooth, and case rates there are correspondingly lower. The second factor is that Australia has unusually thorough reporting systems through the TGA and the Australian Breast Device Registry, so cases here are more likely to be recorded than in countries with less robust surveillance. Practice has shifted significantly since 2019. Most Australian Specialist Plastic Surgeons now use predominantly smooth implants for cosmetic breast augmentation, and the high-risk macro-textured implants aren’t available anymore.
Symptoms to Watch For
Most late changes in the breast around implants aren’t BIA-ALCL. But because BIA-ALCL often shows up first as a sudden new swelling around the implant, it’s something to be aware of and check out properly when symptoms develop.
The most common presentation is breast swelling caused by fluid building up around the implant (called a seroma), appearing years after the original surgery. Other things to keep an eye out for include a noticeable change in size or shape (usually on one side), a new lump in the breast or armpit, pain that doesn’t settle, skin changes such as redness, rash, or thickening, late-onset capsular contracture (firming or tightening of scar tissue), or new asymmetry between the two breasts.
None of these symptoms is specific to BIA-ALCL. Most late seromas turn out to be something else when tested. But any of these changes appearing years after implant surgery is worth getting checked, particularly if your implants are textured or polyurethane-coated. The reason early evaluation matters is that BIA-ALCL outcomes are usually good when caught early. Delays in diagnosis can let the disease progress, and that makes treatment more involved.
How BIA-ALCL Is Diagnosed
If your surgeon has any concern about BIA-ALCL based on what you describe and what they find on examination, the workup follows a fairly standard sequence. The starting point is usually an ultrasound, which can identify fluid collections, masses, or unusual lymph nodes around the implant. If there’s fluid present, an ultrasound-guided needle drains a sample (usually at least 50 millilitres) and sends it to the lab. The lab tests the fluid for cytology, CD30 immunohistochemistry, and often flow cytometry to characterise any abnormal cells and rule out other types of lymphoma. BIA-ALCL cells are typically CD30-positive and ALK-negative, which helps distinguish them from other lymphomas. If the aspiration result isn’t clear but suspicion remains, a biopsy of the capsule itself may be needed.
MRI is sometimes used for more detailed assessment, particularly when ultrasound findings need clarification. In Australia, MBS item 63547 specifically applies to MRI for patients with a confirmed diagnosis of BIA-ALCL where MRI is required for assessing the disease. It isn’t a general first-line imaging item for any breast implant symptoms.
Once BIA-ALCL is confirmed, additional staging investigations (typically a PET-CT scan) determine whether the disease has spread beyond the breast. The whole pathway is run by a multidisciplinary team that includes the plastic surgeon, a haematologist with lymphoma expertise, radiology, and pathology services. You won’t be navigating it alone.
Treatment
Surgery is the cornerstone of BIA-ALCL treatment, and it’s a more involved procedure than routine implant removal. The goal is complete capsulectomy with removal of both implants, even on the side without disease in many cases. Where it’s technically feasible, surgeons aim to remove the implant and capsule en bloc, meaning in one piece, because this may reduce the risk of leaving disease behind. If lymph nodes look involved, they may also be sampled or removed.
For patients diagnosed early, when the disease is confined to the capsule and removed completely with surgery, the prognosis is generally favourable. Contemporary case series report high long-term disease-free survival rates in this group. More advanced cases (with lymph node involvement or disease that has spread beyond the capsule) need additional treatment. Chemotherapy, often anthracycline-based regimens combined with CD30-targeted agents like brentuximab vedotin, is used for these cases. Radiotherapy may be considered in selected situations. Stem cell transplantation is rarely used and remains under research. Treatment decisions in advanced disease are made by a multidisciplinary team and require longer-term follow-up.
MBS item 45551 covers the surgical removal of breast implants and their surrounding capsule. For BIA-ALCL specifically, this MBS pathway typically applies, with appropriate documentation of the diagnosis and staging.
What About BIA-SCC?
In September 2022, the FDA flagged a different and even rarer condition: Breast Implant-Associated Squamous Cell Carcinoma, or BIA-SCC. This isn’t the same disease as BIA-ALCL. BIA-SCC is a different type of cancer (epithelial, meaning it arises from skin-type cells, rather than a lymphoma). It’s much rarer than BIA-ALCL, with only a small number of cases reported worldwide so far in the literature and regulatory databases. The FDA describes it as rare but an emerging concern. It tends to present later, typically 15 to 40 years after implant placement, and early case series suggest it can be more aggressive than BIA-ALCL when diagnosed late, with higher short-term mortality. Symptoms include unilateral pain, skin changes, redness, and nodules in the implant area.
As of early 2026, the TGA hasn’t highlighted confirmed BIA-SCC cases in Australia, though clinicians are encouraged to report any suspected cases. The same general approach applies: any new breast or skin changes years after implant surgery should be evaluated.
What This Means for You Right Now
If you currently have breast implants, the right response to BIA-ALCL information depends on your situation. The TGA, the Australian Society of Plastic Surgeons, and international regulators don’t recommend removing asymptomatic textured implants just to prevent BIA-ALCL. This applies whether you have Mentor Siltex (where the lifetime risk sits at the low end of the textured range) or older macro-textured implants still in place. Standard monitoring usually means a clinical review every one to two years, plus prompt assessment of anything new (swelling, pain, lumps, skin changes), rather than routine surveillance imaging when you have no symptoms.
If you do notice anything new, see your plastic surgeon. Most symptoms turn out not to be BIA-ALCL, but a clinical review with appropriate imaging is the right step. If you have smooth implants, your BIA-ALCL risk specifically is very low, although standard monitoring still applies. If you don’t know what type of implant you have, contact the clinic where your surgery was performed. They should hold the manufacturer, model, and surface type in your medical record. The Australian Breast Device Registry captures many but not all implant procedures, so your surgical clinic record is the primary source.
For patients who are considering implant removal because of BIA-ALCL concerns, the decision is worth working through carefully rather than reactively. For more, see our guide on deciding to remove breast implants and the Medicare considerations for explant surgery.
Frequently Asked Questions
Do I need to have my breast implants removed because of BIA-ALCL? Probably not, if you have no symptoms. International regulators, including the FDA and TGA, along with the Australian Society of Plastic Surgeons, don’t recommend removing breast implants just because they’re textured. The recommended approach is to be aware of symptoms (especially new breast swelling appearing three or more years after surgery), get reviewed clinically if anything changes, and stay on standard monitoring. If you have macro-textured or polyurethane implants and want to discuss removal as a personal choice rather than a medical necessity, that’s a reasonable conversation to have at consultation, but it isn’t something to do reactively.
What’s my actual risk if I have textured implants? It depends on the type of textured implant. The TGA’s broad category estimates put polyurethane-coated implants at roughly 1 in 1,800, macro-textured at about 1 in 2,400, and micro-textured at around 1 in 18,000. Manufacturer-specific cohort data narrows this further: Allergan Biocell macro-textured implants are estimated at roughly 1 in 2,000 to 1 in 8,500, while Mentor Siltex micro-textured implants sit at around 1 in 36,000 to 1 in 50,000. These are best-available estimates rather than precise numbers, because BIA-ALCL is under-reported and the figures are based on estimated implant sales. There are no confirmed Australian BIA-ALCL cases in patients with only smooth implants.
How long after implant surgery does BIA-ALCL usually appear? Most cases (around 95%) show up between three and fourteen years after the original surgery, with the average being about eight years. The reported range stretches from one year out to 37 years, but presentation in the first three years is uncommon. This is why awareness of symptoms continues for many years after the original surgery, particularly if you have textured or polyurethane-coated implants.
Is BIA-ALCL the same as Breast Implant Illness (BII)? No, they’re entirely different conditions. BIA-ALCL is a confirmed rare cancer with specific diagnostic criteria. It’s a CD30-positive T-cell lymphoma that usually shows up as a late seroma. Breast Implant Illness (BII) is a different category altogether: a constellation of systemic symptoms (fatigue, joint pain, brain fog, rashes) that some patients attribute to their implants. The evidence base for BII is still developing and the conditions follow completely different clinical pathways. For more on BII, see our breast implant illness guide.
What’s the prognosis if BIA-ALCL is diagnosed? For patients with disease confined to the capsule and treated with complete surgical removal of both implants and capsules, international data suggests most patients remain disease-free long-term. Outcomes are generally favourable when the disease is caught early. Advanced disease (with lymph node involvement or spread beyond the capsule) needs additional treatment such as chemotherapy and has more variable outcomes, although these cases still often respond to combined-modality treatment with longer-term haematology-oncology follow-up. This is why early symptom recognition matters.
Book a Consultation
If you have current breast implants and have noticed any new changes (swelling, lump, pain, asymmetry, skin changes), or if you’d like to discuss your implant type and what your actual BIA-ALCL risk looks like, book a consultation with Dr Scott J Turner at our Bondi Junction or Manly clinics. Dr Turner also consults at Brisbane, Canberra, and Newcastle.
For BIA-ALCL-related consultations, please obtain a GP referral before your appointment. Bring any original implant records, operation notes, and any recent imaging if you have them. The consultation will cover an examination, a discussion of your implant type and the current evidence, an imaging recommendation if needed, and an honest conversation about whether anything further is warranted.
Contact our clinic on 1300 437 758 or email [email protected].
This article is general information only and isn’t a substitute for medical advice. BIA-ALCL is a rare condition and diagnosis requires individual clinical assessment. Regulatory guidance and risk data from the TGA, FDA, and manufacturers can change, so recommendations described here in 2026 may differ from future updates. A consultation with a qualified health practitioner is required to assess your individual circumstances.
